Literature DB >> 16375919

Structural basis of the differential stability and receptor specificity of H-2Db in complex with murine versus human beta2-microglobulin.

Adnane Achour1, Jakob Michaëlsson, Robert A Harris, Hans-Gustaf Ljunggren, Klas Kärre, Gunter Schneider, Tatyana Sandalova.   

Abstract

beta(2)-Microglobulin (beta(2)m) is non-covalently linked to the major histocompatibility complex (MHC) class I heavy chain and interacts with CD8 and Ly49 receptors. Murine MHC class I heavy chains can bind human beta(2)m (hbeta(2)m) and peptide, and such hybrid molecules are often used in structural and functional studies. The replacement of mouse beta(2)m (mbeta(2)m) with hbeta(2)m has several functional consequences for MHC class I complex stability and specificity, but the structural basis for this is presently unknown. To investigate the impact of species-specific beta(2)m subunits on MHC class I conformation, we provide a crystallographic comparison of H-2D(b) in complex with LCMV-derived gp33 peptide and either hbeta(2)m or mbeta(2)m. The conformation of the gp33 peptide is not affected by the beta(2)m species. Comparison of the interface between beta(2)m and the alpha(1)alpha(2) domains of the heavy chain in these two crystal structures reveals a marked increase in both polarity and number of hydrogen bonds between hbeta(2)m and the alpha(1)alpha(2) domains of H-2D(b). We propose that the positioning of two hydrogen bond rich regions at the hbeta(2)m/alpha(1)alpha(2) interface plays a central role in the increased overall stability and peptide exchange capacity in the H-2D(b)/hbeta(2)m complex. These two regions act as bridges, holding and stabilizing the underside of the alpha(1) and alpha(2) helices, enabling a prolonged peptide-receptive conformation of the peptide binding cleft. Furthermore, analysis of H-2D(b) in complex with either mbeta(2)m or hbeta(2)m provides a structural explanation for the differential binding of H-2D(b)/hbeta(2)m to both Ly49A and Ly49C. Our comparative structural study emphasizes the importance of beta(2)m residues at positions 3, 6 and 29 for binding to Ly49A and suggests that sterical hindrance by residue K6 on hbeta(2)m impairs the recognition of Ly49C by H-2D(b)/gp33/hbeta(2)m. Finally, comparison of the two H-2D(b) crystal structures implies that the beta(2)m species may affect the strength of TCR recognition by affecting CD8 binding.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16375919     DOI: 10.1016/j.jmb.2005.11.068

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  11 in total

1.  Stability screening of arrays of major histocompatibility complexes on combinatorially encoded flow cytometry beads.

Authors:  Shi Ling Chew; Ming Yan Or; Cynthia Xin Lei Chang; Adam J Gehring; Antonio Bertoletti; Gijsbert M Grotenbreg
Journal:  J Biol Chem       Date:  2011-06-16       Impact factor: 5.157

2.  Two distinct conformations of a rinderpest virus epitope presented by bovine major histocompatibility complex class I N*01801: a host strategy to present featured peptides.

Authors:  Xin Li; Jun Liu; Jianxun Qi; Feng Gao; Qirun Li; Xiaoying Li; Nianzhi Zhang; Chun Xia; George F Gao
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

3.  Diverse peptide presentation of rhesus macaque major histocompatibility complex class I Mamu-A 02 revealed by two peptide complex structures and insights into immune escape of simian immunodeficiency virus.

Authors:  Jun Liu; Lianpan Dai; Jianxun Qi; Feng Gao; Youjun Feng; Wenjun Liu; Jinghua Yan; George F Gao
Journal:  J Virol       Date:  2011-05-11       Impact factor: 5.103

4.  Specificity of amyloid precursor-like protein 2 interactions with MHC class I molecules.

Authors:  Amit Tuli; Mahak Sharma; Naava Naslavsky; Steve Caplan; Joyce C Solheim
Journal:  Immunogenetics       Date:  2008-05-02       Impact factor: 2.846

5.  Dynamics of free versus complexed β2-microglobulin and the evolution of interfaces in MHC class I molecules.

Authors:  Chee-Seng Hee; Monika Beerbaum; Bernhard Loll; Martin Ballaschk; Peter Schmieder; Barbara Uchanska-Ziegler; Andreas Ziegler
Journal:  Immunogenetics       Date:  2012-12-11       Impact factor: 2.846

6.  Inflammation-associated nitrotyrosination affects TCR recognition through reduced stability and alteration of the molecular surface of the MHC complex.

Authors:  Chaithanya Madhurantakam; Adil D Duru; Tatyana Sandalova; John R Webb; Adnane Achour
Journal:  PLoS One       Date:  2012-03-14       Impact factor: 3.240

7.  Rational design of mutations that change the aggregation rate of a protein while maintaining its native structure and stability.

Authors:  Carlo Camilloni; Benedetta Maria Sala; Pietro Sormanni; Riccardo Porcari; Alessandra Corazza; Matteo De Rosa; Stefano Zanini; Alberto Barbiroli; Gennaro Esposito; Martino Bolognesi; Vittorio Bellotti; Michele Vendruscolo; Stefano Ricagno
Journal:  Sci Rep       Date:  2016-05-06       Impact factor: 4.379

8.  Crystal structures of H-2Db in complex with the LCMV-derived peptides GP92 and GP392 explain pleiotropic effects of glycosylation on antigen presentation and immunogenicity.

Authors:  Ida Hafstrand; Daniel Badia-Martinez; Benjamin John Josey; Melissa Norström; Jérémie Buratto; Sara Pellegrino; Adil Doganay Duru; Tatyana Sandalova; Adnane Achour
Journal:  PLoS One       Date:  2017-12-18       Impact factor: 3.240

9.  Dynamically Driven Allostery in MHC Proteins: Peptide-Dependent Tuning of Class I MHC Global Flexibility.

Authors:  Cory M Ayres; Esam T Abualrous; Alistair Bailey; Christian Abraham; Lance M Hellman; Steven A Corcelli; Frank Noé; Tim Elliott; Brian M Baker
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

10.  Allo-Specific Humoral Responses: New Methods for Screening Donor-Specific Antibody and Characterization of HLA-Specific Memory B Cells.

Authors:  Shengli Song; Miriam Manook; Jean Kwun; Annette M Jackson; Stuart J Knechtle; Garnett Kelsoe
Journal:  Front Immunol       Date:  2021-07-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.